Emyria commences US preclinical program for MDMA library Released 18 Sep 22
Latest announcements
Announcement summary
Emyria commences US preclinical program for MDMA library
We’re very EXCITED about our partnership with the specialist neuroscience pre-clinical drug discovery organisation PsychoGenics to analyse our MDMA-like compounds for potential further development.
Emyria has been working with the University of Western Australia to develop MDMA-like compounds to become potential treatments for neurological and psychological disorders.
PsychoGenics has 20 years of experience in research and discovery of disorders of the central nervous system. They use an innovative, proprietary technology called ‘SmartCube’. It employs computer vision and AI to analyse how a drug molecule impacts the behaviour of a mouse to different challenges and collects half a million data points over a single session.
PsychoGenics has previously had great success, and we’re excited to see what therapeutic potential we can identify. Once this project is complete, we will look to move any promising candidates towards clinical studies while also submitting more for analysis and building our pre-clinical database of compounds. This agreement marks the beginning of our US pre-clinical activities.
Follow along our journey at emyria.com and here in the new interactive Investor Hub. We welcome you to ask direct questions and discuss all of our announcements.
Kind regards,
Michael Winlo
Emyria MD, CEO
Ask a question
Your question will be sent privately to Emyria. The company may choose to make this question public.
Investor Q&A's
Start the conversation
Ask Emyria a question about this announcement.